Literature DB >> 12964497

Patient experiences with the performance of tablet score lines needed for dosing.

Nienke Rodenhuis1, Peter A de Smet, Dirk M Barends.   

Abstract

OBJECTIVE: The aim of this study was to measure the experience of patients with score line tablets where breaking was necessary for dosing.
METHOD: In three community pharmacies in the Netherlands, patients were asked about their experiences with the functioning of the score line. The survey was restricted to scored tablets that had to be broken to obtain the prescribed dose. It was also asked what actions were taken by the patient when breaking problems were encountered.
RESULTS: Of all the score line prescriptions included in the study, 36% received a negative evaluation by the patient. The main negative experiences were related to loss of mass after breaking the tablets and difficulty in breaking, reported in 32% and 15%, respectively, of the prescriptions included in the study. In only 28% of the negative experiences had this been reported back to the pharmacy.
CONCLUSION: Many patients experience an unsatisfactory performance of tablets with score lines. Improvement will need a combination of technically better score lines and the alertness of the dispensing pharmacy for breaking problems.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12964497     DOI: 10.1023/a:1024852529628

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  3 in total

Review 1.  Breaking of scored tablets: a review.

Authors:  E van Santen; D M Barends; H W Frijlink
Journal:  Eur J Pharm Biopharm       Date:  2002-03       Impact factor: 5.571

2.  Accuracy of tablet splitting.

Authors:  J T McDevitt; A H Gurst; Y Chen
Journal:  Pharmacotherapy       Date:  1998 Jan-Feb       Impact factor: 4.705

3.  Patients' evaluation of shape, size and colour of solid dosage forms.

Authors:  A B Overgaard; J Højsted; R Hansen; J Møller-Sonnergaard; L L Christrup
Journal:  Pharm World Sci       Date:  2001-10
  3 in total
  8 in total

1.  The frequency of inappropriate tablet splitting in primary care.

Authors:  R Quinzler; C Gasse; A Schneider; P Kaufmann-Kolle; J Szecsenyi; W E Haefeli
Journal:  Eur J Clin Pharmacol       Date:  2006-10-06       Impact factor: 2.953

2.  Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets.

Authors:  Edina Vranić; Alija Uzunović
Journal:  Bosn J Basic Med Sci       Date:  2007-11       Impact factor: 3.363

3.  Weight and content uniformity of lorazepam half-tablets: A study of correlation of a low drug content product.

Authors:  Abdel Naser Zaid; Rowa' J Al-Ramahi; Abeer Abu Ghoush; Aiman Qaddumi; Yara Abu Zaaror
Journal:  Saudi Pharm J       Date:  2012-01-05       Impact factor: 4.330

4.  Prediction of the ease of subdivision of scored tablets from their physical parameters.

Authors:  Koos C van der Steen; Henderik W Frijlink; C Maarten A Schipper; Dirk M Barends
Journal:  AAPS PharmSciTech       Date:  2010-01-15       Impact factor: 3.246

Review 5.  A composite screening tool for medication reviews of outpatients: general issues with specific examples.

Authors:  Peter A G M De Smet; Wilma Denneboom; Cees Kramers; Richard Grol
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Evaluation of Certain Pharmaceutical Quality Attributes of Lisinopril Split Tablets.

Authors:  Khairi M S Fahelelbom; Moawia M M Al-Tabakha; Nermin A M Eissa; Jeevani Javadi
Journal:  Sci Pharm       Date:  2016-10-11

7.  Relationship between Age and the Ability to Break Scored Tablets.

Authors:  Kim Notenboom; Herman Vromans; Maarten Schipper; Hubert G M Leufkens; Marcel L Bouvy
Journal:  Front Pharmacol       Date:  2016-07-26       Impact factor: 5.810

8.  The use of oral suspension and rationally prescribing alternatives may be supplemental to the implementation of clopidogrel new algorithm comprising CYP2C19 pharmacogenetics and drug interactions.

Authors:  Meng Chen; Quan Zhou
Journal:  Ther Clin Risk Manag       Date:  2016-03-02       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.